Evidence map›Paper›PMID 29717111›Full record

ArticleCell death & disease2018

Low doses of LPS exacerbate the inflammatory response and trigger death on TLR3-primed human monocytes.

Marta Monguió-Tortajada, Marcella Franquesa, Maria-Rosa Sarrias, Francesc E Borràs

Open access · goldAbstract read
In one paragraph

Article in Cell death & disease, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
40citing papers in PubMed, 2 pooled it
1.7field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

40 citing papers in PubMed, 2 syntheses or guidelines pooled it, 57 citations in OpenAlex.

  1. Pooled it
  2. Immune capacity determines outcome following surgery or trauma: a systematic review and meta-analysis.European journal of trauma and emergency surgery : official publication of the European Trauma Society · 2020
    Pooled it
  3. A novel two-hit murine model of viral-primed sepsis-associated acute kidney injury.American journal of physiology. Renal physiology · 2026
    Article
  4. Investigation ofVeterinary sciences · 2026
    Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Liposomal Nanotraps NeutralizeInfectious microbes & diseases · 2025
    Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Unravelling the mechanisms causing murepavadin resistance inFrontiers in cellular and infection microbiology · 2024
    Article
  17. Review
  18. Monocyte regulation by gut microbial signals.Trends in microbiology · 2023
    Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 2 countries.

Marta Monguió-TortajadaREMAR-IVECAT Group, Health Science Research Institute Germans Trias i Pujol, Can Ruti Campus, Badalona, Spain.
Marcella FranquesaREMAR-IVECAT Group, Health Science Research Institute Germans Trias i Pujol, Can Ruti Campus, Badalona, Spain.
Maria-Rosa SarriasInnate Immunity Group, Health Sciences Research Institute Germans Trias i Pujol, Badalona, Spain.
Francesc E BorràsREMAR-IVECAT Group, Health Science Research Institute Germans Trias i Pujol, Can Ruti Campus, Badalona, Spain. feborras@igtp.cat.
Institut d'Investigació en Ciències de la Salut Germans Trias i Pujol · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

TLR sensing of pathogens triggers monocyte activation to initiate the host innate immune response to infection. Monocytes can dynamically adapt to different TLR agonists inducing different patterns of inflammatory response, and the sequence of exposure to TLRs can dramatically modulate cell activation. Understanding the interactions between TLR signalling that lead to synergy, priming and tolerance to TLR agonists may help explain how prior infections and inflammatory conditioning can regulate the innate immune response to subsequent infections. Our goal was to investigate the role of MyD88-independent/dependent TLR priming on modulating the monocyte response to LPS exposure. We stimulated human blood monocytes with agonists for TLR4 (LPS), TLR3 (poly(I:C)) and TLR7/8 (R848) and subsequently challenged them to low doses of endotoxin. The different TLR agonists promoted distinct inflammatory signatures in monocytes. Upon subsequent LPS challenge, LPS- and R848-primed monocytes did not enhance the previous response, whereas poly(I:C)-primed monocytes exhibited a significant inflammatory response concomitant with a sharp reduction on cell viability. Our results show that TLR3-primed monocytes are prompted to cell death by apoptosis in the presence of low endotoxin levels, concurrent with the production of high levels of TNFα and IL6. Of note, blocking of TNFR I/II in those monocytes did reduce TNFα production but did not abrogate cell death. Instead, direct signalling through TLR4 was responsible of such effect. Collectively, our study provides new insights on the effects of cross-priming and synergism between TLR3 and TLR4, identifying the selective induction of apoptosis as a strategy for TLR-mediated host innate response.

Indexed as

ApoptosisGene Expression RegulationHumansImidazolesImmunity, InnateInterleukin-6LipopolysaccharidesMonocytesPoly I-CPrimary Cell CultureReceptors, Tumor Necrosis Factor, Type IReceptors, Tumor Necrosis Factor, Type IISignal TransductionToll-Like Receptor 3Toll-Like Receptor 4Toll-Like Receptor 7IL6 protein, humanImidazolesInterleukin-6LipopolysaccharidesPoly I-CReceptors, Tumor Necrosis Factor, Type IReceptors, Tumor Necrosis Factor, Type IIresiquimodTLR3 protein, humanTLR4 protein, humanTLR7 protein, humanTLR8 protein, humanToll-Like Receptor 3Toll-Like Receptor 4Toll-Like Receptor 7Toll-Like Receptor 8Tumor Necrosis Factor-alpha

Identifiers

PMID29717111
PMCPMC5931601
OpenAlexW2802785142

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.